Page 24 - AN-2-2
P. 24
Advanced Neurology A novel approach to mitigate muscle atrophy in GBS
https://doi.org/10.1016/j.cellsig.2005.03.013 49. Winer JB, Hughes RA, Osmond C, (1988), A prospective
study of acute idiopathic neuropathy. I. Clinical features
38. Powers SK, Smuder AJ, Criswell DS, (2011), Mechanistic
links between oxidative stress and disuse muscle atrophy. and their prognostic value. J Neurol Neurosurg Psychiatry,
Antioxid Redox Signal, 15: 2519–2528. 51: 605–612.
https://doi.org/10.1136/jnnp.51.5.605
https://doi.org/10.1089/ars.2011.3973
50. Hughes RA, Swan AV, Raphaël JC, et al., (2007),
39. Appell HJ, Duarte JA, Soares JM, (1997), Supplementation
of Vitamin E may attenuate skeletal muscle immobilization Immunotherapy for Guillain-Barré syndrome: A systematic
atrophy. Int J Sports Med, 18: 157–160. review. Brain, 130: 2245–2257.
https://doi.org/10.1093/brain/awm004
https://doi.org/10.1055/s-2007-972612
51. Hughes RA, Wijdicks EF, Benson E, et al., (2005), Supportive
40. Ikemoto M, Nikawa T, Kano M, et al., (2002), Cysteine
supplementation prevents unweighting-induced care for patients with Guillain-Barré syndrome. Arch Neurol,
ubiquitination in association with redox regulation in rat 62: 1194–1198.
skeletal muscle. Biol Chem, 383: 715–721. https://doi.org/10.1001/archneur.62.8.1194
https://doi.org/10.1515/BC.2002.074 52. Wen P, Wang L, Liu H, et al., (2021), Risk factors for the
severity of Guillain-Barré syndrome and predictors of short-
41. Betters JL, Criswell DS, Shanely RA, et al., (2004), Trolox
attenuates mechanical ventilation-induced diaphragmatic term prognosis of severe Guillain-Barré syndrome. Sci Rep,
dysfunction and proteolysis. Am J Respir Crit Care Med, 11: 11578.
170: 1179–1184. https://doi.org/10.1038/s41598-021-91132-3
https://doi.org/10.1164/rccm.200407-939OC 53. Arsenault NS, Vincent PO, Yu BH, et al., (2016), Influence
of exercise on patients with Guillain-Barré syndrome:
42. Ehmsen JT, Höke A, (2020), Cellular and molecular
features of neurogenic skeletal muscle atrophy. Exp Neurol, A systematic review. Physiother Can, 68: 367–376.
331: 113379. https://doi.org/10.3138/PTC.2015-58
https://doi.org/10.1016/j.expneurol.2020.113379 54. Khan F, Pallant JF, Amatya B, et al., (2011), Outcomes
of high- and low-intensity rehabilitation programme for
43. Little BW, Barlow R, Perl DP, (1982), Denervation modulated persons in chronic phase after guillain-barré syndrome:
changes in mouse skeletal muscle RNA concentration. A randomized controlled trial. J Rehabil Med, 43: 638–646.
Virchows Arch B Cell Pathol Incl Mol Pathol, 39: 1–7.
https://doi.org/10.2340/16501977-0826
https://doi.org/10.1007/BF02892831
55. Bensman A, (1970), Strenuous exercise may impair muscle
44. Medina R, Wing SS, Goldberg AL, (1995), Increase in levels
of polyubiquitin and proteasome mRNA in skeletal muscle function in Guillain-Barre patients. JAMA, 214: 468–469.
during starvation and denervation atrophy. Biochem J, 56. Meythaler JM, DeVivo MJ, Braswell WC, (1997),
307: 631–637. Rehabilitation outcomes of patients who have developed
Guillain-Barreé syndrome. Am J Phys Med Rehabil,
https://doi.org/10.1042/bj3070631
76: 411–419.
45. Wing SS, Haas AL, Goldberg AL, (1995), Increase in
ubiquitin-protein conjugates concomitant with the increase https://doi.org/10.1097/00002060-199709000-00012
in proteolysis in rat skeletal muscle during starvation and 57. Saini RK, Keum YS, (2018), Omega-3 and omega-6
atrophy denervation. Biochem J, 307: 639–645. polyunsaturated fatty acids: Dietary sources, metabolism,
and significance-A review. Life Sci, 203: 255–267.
https://doi.org/10.1042/bj3070639
https://doi.org/10.1016/J.LFS.2018.04.049
46. Medina R, Wing SS, Haas A, et al., (1991), Activation of
the ubiquitin-ATP-dependent proteolytic system in skeletal 58. Calder PC, (2017), Omega-3 fatty acids and inflammatory
muscle during fasting and denervation atrophy. Biomed processes: From molecules to man. Biochem Soc Trans,
Biochim Acta, 50: 347–356. 45: 1105–1115.
47. Shahar E, (2006), Current therapeutic options in severe https://doi.org/10.1042/BST20160474
Guillain-Barré syndrome. Clin Neuropharmacol, 29: 45–51.
59. Covington MB, (2004), Omega-3 fatty acids. Am Fam
https://doi.org/10.1097/00002826-200601000-00011 Physician, 70: 133–140.
48. Uncini A, Kuwabara S, (2018), The electrodiagnosis of 60. McGlory C, Calder PC, Nunes EA, (2019), The influence of
Guillain-Barré syndrome subtypes: Where do we stand? omega-3 fatty acids on skeletal muscle protein turnover in
Clin Neurophysiol, 129: 2586–2593. health, disuse, and disease. Front Nutr, 6: 144.
https://doi.org/10.1016/J.CLINPH.2018.09.025 https://doi.org/10.3389/fnut.2019.00144
Volume 2 Issue 2 (2023) 10 https://doi.org/10.36922/an.280
